Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

被引：4
|
作者：
Breccia, Massimo [1 ]
Molica, Matteo [1 ]
Colafigli, Gioia [1 ]
Zacheo, Irene [1 ]
Latagliata, Roberto [1 ]
Tafuri, Agostino [2 ,3 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
[2] S Andrea Hosp, Hematol, Rome, Italy
[3] Univ Roma La Sapienza, Dept Mol Med, Hematol, I-00161 Rome, Italy
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 07期
关键词：
D O I：
10.3109/10428194.2014.993391
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2206 / 2207
页数：2
相关论文
共 50 条
  • [41] Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib
    Breccia, Massimo
    Palandri, Francesca
    Iori, Anna Paola
    Colaci, Elisabetta
    Latagliata, Roberto
    Castagnetti, Fausto
    Torelli, Giovanni Fernando
    Usai, Sara
    Valle, Veronica
    Martinelli, Giovanni
    Rosti, Gianantonio
    Foa, Robin
    Baccarani, Michele
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2010, 34 (02) : 143 - 147
  • [42] Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML)
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Fava, Carmen
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Komblau, Steven
    Ravandi, Farhad
    Wierda, William
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1104 - 1104
  • [43] Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed
    Ibrahim, Amr R.
    Clark, Richard E.
    Holyoake, Tessa L.
    Byrne, Jenny
    Shepherd, Pat
    Apperley, Jane F.
    Milojkovic, Dragana
    Szydlo, Richard
    Goldman, John
    Marin, David
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (12): : 1779 - 1782
  • [44] Second-Generation Tyrosine Kinase Inhibitors Combined With Stem Cell Transplantation in Patients With Imatinib-Refractory Chronic Myeloid Leukemia
    Zhao, Yanmin
    Luo, Yi
    Shi, Jimin
    Cai, Zhen
    Huang, He
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 347 (06): : 439 - 445
  • [45] Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
    Nakazato, Tomonori
    Iriyama, Noriyoshi
    Tokuhira, Michihide
    Ishikawa, Maho
    Sato, Eriko
    Takaku, Tomoiku
    Sugimoto, Kei-Ji
    Fujita, Hiroyuki
    Fujioka, Isao
    Kimura, Yuta
    Aisa, Yoshinobu
    Iwanaga, Eisaku
    Asou, Norio
    Kizaki, Masahiro
    Hatta, Yoshihiro
    Komatsu, Norio
    Kawaguchi, Tatsuya
    MEDICAL ONCOLOGY, 2018, 35 (07)
  • [46] Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
    Tomonori Nakazato
    Noriyoshi Iriyama
    Michihide Tokuhira
    Maho Ishikawa
    Eriko Sato
    Tomoiku Takaku
    Kei-Ji Sugimoto
    Hiroyuki Fujita
    Isao Fujioka
    Yuta Kimura
    Yoshinobu Aisa
    Eisaku Iwanaga
    Norio Asou
    Masahiro Kizaki
    Yoshihiro Hatta
    Norio Komatsu
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
  • [47] Vascular complications in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Cho, Hee Jeong
    Sohn, Sang-Kyun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (04): : 224 - 233
  • [48] Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
    Sawyers, CL
    SEMINARS IN HEMATOLOGY, 2001, 38 (03) : 15 - 21
  • [49] MONITORING CLINICAL CARDIOLOGY WITH TRANSTHORACIC ECHOCARDIOGRAPHY AND ELECTROCARDIOGRAPHY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS SECOND GENERATION
    Ayala, M.
    Bonilla, I.
    Domnguez, J.
    Aquino, X.
    Flores, A.
    HAEMATOLOGICA, 2015, 100 : 701 - 701
  • [50] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Devendra, K. C.
    Akosile, Mary
    Borthakur, Gautam
    Verstovsek, Srdan
    Daver, Naval
    Pemmaraju, Naveen
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Ravandi, Farhad
    Konopleva, Marina
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
12345